![]() ![]() ![]() The study demonstrates that these policies would affect a small number of drugs but could generate billions in savings to Medicare and private payers by contributing to increased competition. The study examines two policies to reform the Orphan Drug Act incentives: granting market exclusivity only for drugs whose combined population across all orphan indications is lower than 200 000 individuals, and granting market exclusivity only for drugs that exclusively treat orphan populations, ie, drugs without a nonorphan indication. There are concerns that the incentives established in the Orphan Drug Act have been granted to drugs that would be financially viable without those incentives, contributing to keeping prices high and warding off competition. Orphan drugs have become a growing source of spending in recent years because of ever-increasing prices and more orphan drugs entering the market.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |